Article info

Original research
Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism

Authors

  • Lisa A de Jong Unit of Pharmacotherapy, Epidemiology and Economics, University of Groningen, Groningen, The Netherlands PubMed articlesGoogle scholar articles
  • Annette W G van der Velden Department of Internal Medicine, Martini Hospital, Groningen, The Netherlands PubMed articlesGoogle scholar articles
  • Marinus van Hulst Department of Clinical Pharmacy and Toxicology, Martini Hospital, Groningen, The NetherlandsDepartment of Health Sciences, University Medical Centre Groningen, Groningen, The Netherlands PubMed articlesGoogle scholar articles
  • Maarten J Postma Department of Health Sciences, University Medical Centre Groningen, Groningen, The NetherlandsDepartment of Economics, Econometrics & Finance, University of Groningen, Groningen, The Netherlands PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Lisa A de Jong; l.a.de.jong{at}rug.nl
View Full Text

Citation

de Jong LA, van der Velden AWG, Hulst MV, et al
Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism

Publication history

  • Received April 6, 2020
  • Revised October 13, 2020
  • Accepted October 27, 2020
  • First published November 19, 2020.
Online issue publication 
November 19, 2020
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.